{"id":4186,"date":"2025-03-27T16:45:47","date_gmt":"2025-03-27T15:45:47","guid":{"rendered":"https:\/\/www.genexpath.com\/?page_id=4186"},"modified":"2025-03-31T11:29:12","modified_gmt":"2025-03-31T09:29:12","slug":"lymphosign","status":"publish","type":"page","link":"https:\/\/old.genexpath.com\/en\/nos-produits\/lymphosign\/","title":{"rendered":"LymphoSign test"},"content":{"rendered":"
<\/span>\"Banni\u00e8re
\n
\n
\n

LymphoSign test<\/strong><\/h1>\n\n\n\n

A fine classification of non-Hodgkin's lymphomas<\/h2>\n<\/div>\n<\/div><\/div>\n<\/div><\/div>\n\n\n\n
\n
\n
Home<\/a><\/span> \u00bb Our products<\/a><\/span> \u00bb LymphoSign test<\/span><\/span><\/div><\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n
\n
<\/div>\n\n\n\n
\n

The in-depth understanding of non-Hodgkin lymphoma (NHL) has become a major challenge, and many advances have been made since the introduction of the WHO classification in 2001.<\/p>\n\n\n\n

However, the risk of diagnostic errors remains high due to the great diversity of lymphomas. There are in fact more than 80 subtypes of non-Hodgkin lymphoma, some of which are rare and particularly complex to characterize.<\/p>\n\n\n\n

The LymphoSign test<\/strong> However, the risk of diagnostic errors remains high due to the great diversity of lymphomas. There are in fact more than 80 subtypes of non-Hodgkin lymphoma, some of which are rare and particularly complex to characterize.<\/p>\n\n\n\n

This test is marked CE-IVD<\/strong> for diagnostic use in Vitro test<\/em>, guaranteeing its compliance with European safety and performance requirements.<\/p>\n\n\n\n

\n
\n

This test is suitable for classifying the following subgroups: <\/p>\n\n\n\n